Dimensional Fund Advisors’s Inhibikase Therapeutics IKT Stock Holding History

Dimensional Fund Advisors’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$211K	Buy	+103,073	New	+$235K	﹤0.01%	3059

Other funds holding IKT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Xponance Philadelphia, Pennsylvania $17.2B AUM 36.34% 1-Year Est. Return

Dimensional Fund Advisors's IKT Position: Q3 2026 in Review

Dimensional Fund Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q3 2026: 103,073 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #3059 among its holdings.

25 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

Dimensional Fund Advisors held 103,073 shares of Inhibikase Therapeutics worth $211K as of Q3 2026.
Inhibikase Therapeutics was a new Dimensional Fund Advisors position in Q3 2026.
Inhibikase Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3059 holding.
25 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.